About KanTil Pharmaceuticals
KanTil Pharmaceuticals is an Industrial Goods & Manufacturing company. Pharmaceutical manufacturing, distribution, and RD services in India. It operates in the Industrial Goods & Manufacturing and Healthcare sectors. Its Indian entity Kantil Pharmaceuticals Private Limited reported revenue of ₹29.42 Cr. KanTil Pharmaceuticals offers products and services including Tablets and Capsules and Injectables and Onco Products. Its focus areas include Chemicals, Industrial Supplies, API and Chemicals and Raw Materials.
Company details
KanTil Pharmaceuticals is known for its focus on innovation in the pharmaceutical sector, where a wide array of products such as tablets, capsules, syrups, and creams is manufactured and prepared for export. RD efforts are maintained to develop new formulations in speciality areas, and partnerships with exporters are established to expand reach. Quality services are provided as a one-stop solution for healthcare needs, with ethical practices and customer-oriented approaches being emphasized in operations. Adherence to standards ensures timely delivery of medicines.
- SectorsIndustrial Goods & ManufacturingHealthcare
- Email••••••••
- Phone•••• ••••
- Website kantil.in
- Social LinkedIn Facebook Instagram
- Legal Name Kantil Pharmaceuticals Pvt Ltd
- Date of Incorporation 08 Oct, 2021
- Jurisdiction Delhi, India
- Indian entity revenue₹29.42 Cr
FY 2024 · +924% YoY
- Indian entity net profit₹36.8 Lakh
FY 2024 · 1% margin
- Indian entity EBITDA₹2.62 Cr
FY 2024 · 9% margin
Associated legal entities of KanTil Pharmaceuticals
KanTil Pharmaceuticals operates through Kantil Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Kantil Pharmaceuticals Private Limited CIN U24230DL2021PTC387973 | Active | 08 Oct 2021 | Delhi, Delhi | ₹29.4 Cr | 33 | 3 | View details |
Products & Services of KanTil Pharmaceuticals
KanTil Pharmaceuticals offers a comprehensive portfolio of products and services, including Tablets and Capsules and Injectables and Onco Products.
Tablets and capsules are produced for various medicinal uses, covering a range of formulations.
Injectables and oncology products are manufactured through tie-ups with other entities.
Board of directors of Kantil Pharmaceuticals Private Limited (KanTil Pharmaceuticals)
Kantil Pharmaceuticals Private Limited is the primary company behind KanTil Pharmaceuticals. The board of Kantil Pharmaceuticals Private Limited currently have 3 directors; the longest-serving is Shikha Gupta, appointed in 2021. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shikha Gupta DIN 09352421 | Director | 08 Oct 2021 | 5 yrs | Kantil Pharmaceuticals Private Limited |
| Nitin Gupta DIN 02629085 | Director | 08 Oct 2021 | 5 yrs | Kantil Pharmaceuticals Private Limited |
| Sarika Gupta DIN 09550517 | Director | 08 Apr 2022 | 4 yrs 7 mo | Kantil Pharmaceuticals Private Limited |
Financials of KanTil Pharmaceuticals
Figures of Kantil Pharmaceuticals Private Limited, the primary company behind KanTil Pharmaceuticals, for FY 2024. Revenue was ₹29.42 Cr (+924% year on year). Net profit was ₹36.8 Lakh (1% margin). EBITDA was ₹2.62 Cr (9% margin).
- ₹29.42 CrRevenue · FY 2024 · +924% YoY
- ₹36.8 LakhNet profit · 1% margin
- ₹2.62 CrEBITDA · 9% margin
- ₹35 LakhPaid-up capital
- 33Employees (provident fund records)
Balance sheet, profit and loss, cash flow and ratios of Kantil Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for KanTil Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about KanTil Pharmaceuticals
The primary company behind KanTil Pharmaceuticals, Kantil Pharmaceuticals Private Limited, reported revenue of ₹29.42 Cr for FY 2024, up 924% year on year.
KanTil Pharmaceuticals is known for its focus on innovation in the pharmaceutical sector, where a wide array of products such as tablets, capsules, syrups, and creams is manufactured and prepared for export. RD efforts are maintained to develop new formulations in speciality areas, and partnerships with exporters are established to expand reach. Quality services are provided as a one-stop solution for healthcare needs, with ethical practices and customer-oriented approaches being emphasized in operations. Adherence to standards ensures timely delivery of medicines.
KanTil Pharmaceuticals offers Tablets and Capsules and Injectables and Onco Products.
KanTil Pharmaceuticals operates through Kantil Pharmaceuticals Private Limited.
The legal entities of KanTil Pharmaceuticals currently have 3 directors, including Shikha Gupta, Nitin Gupta, Sarika Gupta.